Tesis

Perbandingan Kesintasan Pasien Dengan Keganasan Ovarium Sel Germinal Yang Diberikan Kemoterapi Ajuvan Bleomycin, Etoposide, dengan Platinum Based Dengan Carboplatin Dan Paclitaxel = Comparison of Survival Between Bleomycin-EtoposidePlatinum-based Chemotherapy versus Carboplatin-Paclitaxel Chemotherapy in Germ Cell Ovarian Cancer Patients.

Latar Belakang: Keganasan ovarium sel germinal (KOSG) adalah tumor ovarium yang umum pada usia muda, meskipun jarang dibandingkan keganasan ovarium epitelial. KOSG pada stadium II-IV cenderung lebih agresif dan memerlukan kemoterapi ajuvan. Penelitian ini bertujuan membandingkan kesintasan pasien KOSG yang menerima kemoterapi Bleomycin-Etoposide-Platinum Based (BEP) dan Carboplatin-Paclitaxel (CP). Metode: Studi kohort retrospektif ini menggunakan data rekam medis pasien KOSG yang menerima kemoterapi BEP atau CP di tiga rumah sakit di Jakarta dan Tangerang, dari Agustus 2024 hingga April 2025. Analisis dilakukan dengan Kaplan-Meier, uji Log Rank, dan regresi Cox. Hasil: Sebanyak 65 subjek penelitian terdiri dari 37 pasien yang menerima kemoterapi BEP dan 28 pasien yang menerima kemoterapi CP. Tidak terdapat perbedaan signifikan antara kelompok BEP dan CP pada OS dan PFS. Residu tumor > 1 cm dan keterlambatan kemoterapi > 1 minggu berhubungan signifikan dengan kematian (HR 14,399; 95% CI 2,765–74,984, p=0,002) dan progresi tumor (HR 12,610; 95% CI 3,593–44,255, p < 0,001). Analisis subgrup menunjukkan kedua variabel tersebut mempengaruhi PFS dan OS pada pasien BEP. Kesimpulan: Tidak terdapat perbedaan signifikan pada OS dan PFS antara kedua regimen kemoterapi. Residu tumor >1 cm dan keterlambatan kemoterapi > 1 minggu mempengaruhi kesintasan pasien dengan kemoterapi BEP.


Background: Germ cell ovarian cancer (GCOC) is a common tumor in young women, though less frequent than epithelial ovarian cancer. In stages II-IV, GCOC is more aggressive and requires adjuvant chemotherapy. This study compares the survival of GCOC patients receiving Bleomycin-Etoposide-Platinum Based (BEP) chemotherapy and Carboplatin-Paclitaxel (CP) chemotherapy. Methods: This retrospective cohort study analyzed medical records of GCOC patients receiving BEP or CP chemotherapy at three hospitals in Jakarta and Tangerang from August 2024 to April 2025. Data were analyzed using Kaplan-Meier, Log Rank test, and Cox regression. Results: A total of 65 patients were included, with 37 receiving BEP and 28 receiving CP. No significant difference in OS and PFS was found between the groups. Tumor residue >1 cm and chemotherapy delay >1 week were significantly associated with mortality (HR 14.399; 95% CI 2.765–74.984, p=0.002) and progression (HR 12.610; 95% CI 3.593–44.255, p < 0.001). Subgroup analysis showed these variables affected PFS and OS in the BEP group. Conclusion: No significant differences in OS and PFS between the two regimens. Tumor residue >1 cm and chemotherapy delay >1 week affect survival in BEP-treated patients.
Keywords: ovarian cancer; germ cell; adjuvant chemotherapy